The report carefully examines the Direct-To-Consumer (DTC) Genetic Testing Market, with a focus on most of the major players and their business strategies, geographical scope, market segments, product landscape and price and cost structure. Each section of the research study is specially prepared to investigate key aspects of the Direct-To-Consumer (DTC) Genetic Testing market. The area of market activity, for example, drivers, restrictions, trends and opportunities in the global market for Direct-To-Consumer (DTC) Genetic Testing is explored in detail. Through qualitative and quantitative analysis, we support you in a comprehensive and comprehensive analysis of the Direct-To-Consumer (DTC) Genetic Testing market. We also focus on the five forces analysis of SWOT, PESTLE and Porter in the Direct-To-Consumer (DTC) Genetic Testing market.

Direct-to-Consumer (DTC) Genetic Testing Market was valued at USD 789.92 Million in 2018 and is projected to reach USD 2,361.12 Billion by 2026, growing at a CAGR of 14.59% from 2019 to 2026.

Request a Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=25584&utm_source=NPN&utm_medium=003

The main Companies operating in the Direct-To-Consumer (DTC) Genetic Testing Market are listed in the report.

Direct-To-Consumer (DTC) Genetic Testing Market: Competitive Landscape

The players who lead the Direct-To-Consumer (DTC) Genetic Testing market are analyzed taking into account their market share, the latest developments, new manufacturers, associations, acquisitions and markets. We also provide a comprehensive analysis of your product portfolio to explore the product and the applications that you focus on while operating in the Direct-To-Consumer (DTC) Genetic Testing market. In addition, the report offers two different market forecasts: one is the production side and the other on the use side of the Direct-To-Consumer (DTC) Genetic Testing market. It also provides practical advice for newcomers, as well as for established players in the world of smart camera market.

Direct-To-Consumer (DTC) Genetic Testing Market: Segment Analysis

This chapter focuses on the different segments in the Direct-To-Consumer (DTC) Genetic Testing market. The report segments the market by type, application, product, service and end user. This division enables a detailed view of the motif. It helps to understand the changes in production and the general needs of consumers that are likely to affect these segments.

Direct-To-Consumer (DTC) Genetic Testing Market: Regional Analysis

The chapter on regional analysis highlights the political scenario in emerging and industrialized countries that is expected to affect the dynamics of supply and demand. Regional analysis also helps identify the changing needs of the population that have a critical impact on the general market for Direct-To-Consumer (DTC) Genetic Testing . This part of the research report also took into account labor costs, raw materials and production costs by region.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=25584&utm_source=NPN&utm_medium=003

Table of Content

1 Introduction of Direct-To-Consumer (DTC) Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Direct-To-Consumer (DTC) Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Direct-To-Consumer (DTC) Genetic Testing Market , By Deployment Model

5.1 Overview

6 Direct-To-Consumer (DTC) Genetic Testing Market , By Solution

6.1 Overview

7 Direct-To-Consumer (DTC) Genetic Testing Market , By Vertical

7.1 Overview

8 Direct-To-Consumer (DTC) Genetic Testing Market , By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Report Customization @ https://www.verifiedmarketresearch.com/product/Direct-To-Consumer-DTC-Genetic-Testing-Market/?utm_source=NPN&utm_medium=003

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Direct-To-Consumer (DTC) Genetic Testing Market Size, Direct-To-Consumer (DTC) Genetic Testing Market Growth, Direct-To-Consumer (DTC) Genetic Testing Market Forecast, Direct-To-Consumer (DTC) Genetic Testing Market Analysis, Direct-To-Consumer (DTC) Genetic Testing Market Trends, Direct-To-Consumer (DTC) Genetic Testing Market

See the original post here:
Direct-To-Consumer (DTC) Genetic Testing Market Size, Current Trends, Business Opportunities, Market Challenges and Analysis by 2026 - News Parents

Recommendation and review posted by Bethany Smith

Agriculture is responsible for the production of a quarter of the total human-generated greenhouse gases. Growing food also uses about 70 percent of the water available to us. Moreover, agriculture (especially meat production) is the single most significant driver of deforestation and biodiversity loss. Food production is detrimental to the health of the planetbut it doesnt end there. Once the food reaches plates, poor-quality diets cause malnutrition, claiming more lives than tobacco, drug and alcohol combined.

Search for malnutrition online and you will see pictures of frail and sick children. But along with stunting, wasting, vitamin and mineral deficiency, malnutrition also includes overweight, obesity and other diet-related illnesses. Yes, 1 in 9 people around the world go to sleep hungry, but nearly 2 billion adults are also overweight or obese. As such, more than one-third of the world population suffers from at least one form of malnutrition.

With the climate and biodiversity crises, and the global public-health crisis in the form of malnutrition, we must find a healthy and environmentally sustainable diet to feed the growing population. In 2019, the EAT-Lancet Commission brought together leading experts in nutrition, health, sustainability and policy to recommend ways to transform the global food system to achieve a healthy and sustainable diet.

The EAT-Lancet report recommends that planetary health diets to feed 10 billion people by 2050 requires cutting down meat consumption by half and eating twice as much as fruits, vegetables, beans and nuts. Despite recognizing the need to make healthy food affordable for the poor, the EAT-Lancet Commission didnt review the cost and affordability of the ideal diet. Therefore, in a recent global study, scientists reviewed prices for nearly 750 food items to calculate the value of healthy and sustainable diets in 159 countries.

The research, published in Lancet Global Health, shows that many people in low and lower-middle-income countries are too poor to afford EAT-Lancets ideal diet. EAT-Lancet says that we would need to eat twice as much as many fruits and vegetables, and get more protein and fats from plant-source foods. However, the new study found that fruits, vegetables, beans and nuts are the most expensive items of the ideal diet accounting for half of its total price.

Shifting foodsystems

A key challenge of the 21st-century is to change our food system to produce a healthy diet that is both economically and environmentally sustainable. As EAT-Lancets ideal diet isnt affordable for much of the worlds low-income population, authorities must make several parallel interventions to tackle global food inequality.

Lower food prices and higher earnings would give poor people more purchasing power. We must also find cheaper, nutritious food alternatives that are affordable and accessible to people living in low-income areas. I believe that biotechnology has the power to lower the cost of locally and globally grown food, making the ideal diet economically viable to those that need it the most.

One problem is the lack of available, affordable options, which partly stems from decreasing agrobiodiversity. Just three crops (rice, wheat and corn) provide over half of the plant-derived calories worldwide. Shifting calories away from the starchy staple foods towards more nutritious fruits, vegetables and other protein-sourced food remains a significant challenge in meeting EAT-Lancet targets. Grand challenges require great technological solutions, and genetic engineering technology is among the most powerful tools at our disposal.

Power of biotechnology

Biotechnology can improve agrobiodiversity and provide more locally-grown food options for people in low-income areas. One way to do this would be to make inedible plants into a good source of nutrition and calories. Take cottonseed, for example, which has the potential to be a cheaper alternative to nuts. Cottonseeds are highly nutritious, containing oils and proteins in abundance, but many low-income cotton farmers cant eat cottonseeds because they produce toxins called gossypol.

Now, scientists have engineered cotton plants to remove the toxin, making cottonseeds safe for us to eat. And recently, the U.S. Food and Drug Administration approved genetically modified (GM) cottonseed for human consumption. Biotech cottonseed can act as an excellent alternative dietary source in low-income regions, where people struggle to meet the costs of the ideal diet recommended by EAT-Lancet.

Genetic engineering can also enable widespread cultivation of local plants. The groundcherry plant in its native form has a wild, sprawling growth habit which causes its fruits to drop to the ground while still small. Difficulties in cultivating the wildcherry mean its an orphan plant. However, scientists used genetic engineering to improve wildcherrys undesirable traits, including the plants weedy shape, flower production and fruit size. Now there are hopes for large-scale cultivation of genetically engineered groundcherry, which is native to Central and South America.

Millions of children and adults around the world suffer from micronutrient deficiencies, and biotechnology can also help fortify current crops to improve their vitamin and micronutrient contents. For example, scientists have recently developed biofortified cassava, which has higher zinc and iron contents than regular cassava. The biofortified cassava may one day prevent illnesses related to iron and zinc deficiencies.

Golden Rice is perhaps the prime example of a biofortified cropconventional rice that is genetically engineered to produce the vitamin A precursor beta-carotene. Golden Rice, acting as a source of vitamin A, can address vitamin A deficiency that blinds and kills hundreds of thousands of children every year. After a rigorous biosafety assessment in the Philippines, the Department of Agriculture-Bureau of Plant Industry found Golden Rice to be safe as conventional rice. Golden Rice regulation application is under review in Bangladesh, as well. This biofortified crop can provide much-needed micronutrients, taking the everyday staple food further to meet peoples dietary requirements in the poorest regions of the world.

Economic benefits

Improved agrobiodiversity and availability of local food varieties, enabled by biotechnology, will bring down the cost of the ideal diet, reducing food inequality. But GM technology also has the power to lift people out of poverty and increase the spending power of the low-income communities in developing regions.

Higher farm productivity, especially in low-income areas, can lower food prices. A meta-analysis of studies published after 1995 found that adopting GM technology has widespread benefits, including economic gains for farmers that grow GM crops. The meta-analysis found that GM technology increases crop yields by 21 percent. Some GM crops are engineered to be more resistant to pest damage, which helps achieve higher yields, for example.

The meta-study also found that GM crops require 37 percent less pesticide, which reduces pesticide costs by 39 percent and helps spare the environment. Even though GM seeds are more expensive than non-GM seeds, savings in pest control and pesticide use mean that farmers adopting GM crops enjoy 68 percent more profit. Therefore, GM crops can increase farmers spending power, which is excellent news for the quarter of the worlds working population employed in agriculture . More importantly, the yield and profit from GM crops are higher in developing countries than in developed countries.

If adopted widely, genetic engineering technology will bring us closer to meeting the EAT-Lancet dietary targets, which will help us protect the environment, public health, and reduce inequality.

Rupesh Paudyal holds a PhD in plant science and covers agriculture and the environment as a freelance writer. Visit his website and follow him on Twitter @TalkPlant

More here:
Viewpoint: We can sustainably feed 10 billion people. Here's how CRISPR and GMO crops can help - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

Traditional agriculture requires many inputs; fertilizer, specific chemicals, manual labor and water. Most of the water used in agriculture is for irrigation, and some crops require more water to grow than others. Rice is one of the most water-intensive crops, and also one of the most widely consumed worldwide.

Manipulating the rice genome is not entirely new. The Golden Rice Project emerged in 1999 to address the rampant vitamin A deficiency, and resulting blindness in manycountries where rice is a staple food. Other research into increasing photosynthetic efficiency, drought resistance, and methane reduction of rice is in the works as well, and all requires genetic modification.

Opposition to genetically modified organisms (GMOs) in food has halted progress on a project that the founders believe could save billions of people who eat rice every day. GMO use is a divisive topic, and many scientists and companies are choosing to stay away from them to avoid public disdain and regulatory challenges.

Agrisea is taking a different approach to food science. They want to grow rice in the ocean by using gene-editing, which would amplify the expression of genes already found in rice that control salt-tolerance. Salt-tolerant rice could be grown in salty ocean water without the use of soil, fertilizer or fresh water. Rather than inserting genes from other species, they have identified the genes that control for salt expulsion, cellular insulation and DNA protection, and are enhancing the expression of those genes.

Together these genes act in a network, just like they do in nature, Luke Young, CEO and co-founder of Agrisea said. We just encourage them along the pathways that nature has formed in plants that can thrive in a salty environment. The co-founders explained that they could use repeated selective breeding in rice to get the same result, but gene-editing just speeds up the process.

Read the original post

Read more:
Gene editing 'rice revolution': CRISPR could be used to grow one of the world's most important crops in salt water - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

Global CRISPR and CAS Gene Marketreport includes the worlds crucial region market share, size (volume), recent trends including the product profit, value (revenue), price, production, supply/demand, capability utilization, and industry growth rate.

The Global CRISPR and CAS Gene Market2020-2026 Research Report offers extended insights on requisite forecasts of the CRISPR and CAS Gene market trends and macro and micro factors. Also, this report serves to understand the measures that are operating and restraining the requirement and application in the CRISPR and CAS Gene market. However, the research explores the main highlights of the current market trends and gives a prediction for the CRISPR and CAS Gene industry future.

The competitive evaluation of the application market brings monitoring into the product usage types of the present top players. Also, the study highlights characteristic features & CRISPR and CAS Gene price, beneficial reviews on the crucial products in the worldwide market. The report offered key facts and figures on the CRISPR and CAS Gene market statistics, key competitors and is an important source of guidance and business direction and an individuals interests in the CRISPR and CAS Gene industry.

Get Free Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2598

This report provides an overview of the CRISPR and CAS Gene industry, including its basic introduction, applications, and advanced manufacturing techniques. So as to get a more extreme view of the market size, the competitive landscape is served. This includes CRISPR and CAS Gene market revenue share (%) by key players (2013-2018) and revenue (in Million USD) by top leading companies (2013-2018).

Competitive Analysis:

The major companies are exceedingly focused on innovation in CRISPR and CAS Gene production technology to enhance ledge life and efficiency. The best long-term development path for CRISPR and CAS Gene market can be caught by guaranteeing financial pliancy to invest in the optimal strategies and current process improvement.

The CRISPR and CAS Gene industry company profile section ofCaribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Each manufacturer or CRISPR and CAS Gene market players growth rate, revenue figures, and gross profit margin is provided in a tabular, simple format for few years and an individual section on CRISPR and CAS Gene market recent development such as collaboration, acquisition, mergers, and any new service or new product launching in the market is offered.

Topographical Study: Europe, US, Japan, Southeast Asia, and Central & South America, China and India.

A detailed profile for more than 10 leading manufacturers is included, along with the financial history, to analyze the latest performance of the CRISPR and CAS Gene market. Latest and revised discussion of major CRISPR and CAS Gene market and influences the market is considered with a thought-provoking qualitative state on CRISPR and CAS Gene market future threats, challenges, and opportunities. This report integrates the best of statistically applicable quantitative data from the CRISPR and CAS Gene industry, along with detailed and relevant qualitative study and comment.

Purchase Copy of This Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2598

Customized country-level and region-wise reports for the following regions:

North America: US, Canada, and Mexico.

South & Central America: Chile, Argentina, and Brazil.

Middle East & Africa: UAE, Turkey, Saudi Arabia, Egypt, and South Africa.

Europe: United Kingdom, France, Spain, Italy, Germany, and Russia.

Asia-Pacific: Japan, India, China, Singapore, South Korea, Indonesia, and Australia.

The following years taken into consideration in this research to forecast the global CRISPR and CAS Gene market size are as follows:

History Year: 2013-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year: 2020 to 2026

Download The Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2598

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Name: Mr.ShahPhone: US +12067016702 / UK +4402081334027Email:[emailprotected] Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

See the rest here:
CRISPR and CAS Gene Market Demand Analysis by 2026 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc.,...

Recommendation and review posted by Bethany Smith

Nearly 1.8 million Americans were diagnosed with cancer last year. Around the world, the total was close to 17 million. It's not surprising, then, that more than 700 biopharmaceutical companies have experimental cancer drugs in late-stage development.

Beta-thalassemia, on the other hand, is a rare disease that affects around 1,000 or so people in the United States. It's more prevalent in some countries but still impacts only one in 100,000 individuals.

You might expect one or maybe two biotechs could be developing therapies to treat beta-thalassemia. However, by my count, at least half a dozen companies have programs targeting the blood disorder. Why are a disproportionate number of biotechs scrambling to develop drugs for the same rare disease?

Image source: Getty Images.

Probably the main reason why a relatively large group of drugmakers are targeting beta-thalassemia is that the cause of the disease is straightforward. Understanding the why behind a disease is a critical prerequisite to treating it.

Beta-thalassemia is usually caused by a mutation in the HBB gene, which provides instructions on how to build beta-globin proteins. These proteins are part of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. The HBB mutations that cause beta-thalassemia result in dysfunctional red blood cells that can't carry enough oxygen, which leads to patients experiencing anemia.

Another potential reason why biotechs are attracted to beta-thalassemia, though, is that it's not the only disease that is caused by mutations in the HBB gene. Sickle cell disease (SCD) is a related disease where HBB mutations cause red blood cells to form a sickle (or crescent) shape. These misshaped red blood cells can get stuck in blood vessels and cause multiple health complications, including anemia, infections, frequent pain, and heart problems.

While beta-thalassemia is rare, SCD is the most common genetic blood disorder in the U.S. It affects up to 100,000 Americans. SCD is even more prevalent in Africa, impacting up to 3% of newborns in some parts of the continent.

Drugmakers that identify a way to treat beta-thalassemia can be on the right track to target sickle cell disease as well. And with a much larger patient population, the market potential for successful therapies is greater.

One product has already been approved by the FDA for treating beta-thalassemia. Acceleron Pharma (NASDAQ:XLRN) developed luspatercept in collaboration with Celgene. In November 2019, Celgene won FDA approval for luspatercept in treating transfusion-dependent beta-thalassemia. Bristol-Myers Squibb (NYSE:BMY) closed its acquisition of Celgene a few weeks later and is marketing the drug under the brand name Reblozyl. Luspatercept is also in a mid-stage clinical study for treating non-transfusion-dependent beta-thalassemia.

Bluebird bio (NASDAQ:BLUE) won European approval for Lentiglobin in June 2019 for treating transfusion-dependent beta-thalassemia. Lentiglobin is a gene therapy that transplants cells with healthy HBB genes into patients. The biotech launched the therapy in Germany in January with the brand name Zynteglo. Bluebird plans to roll out Zynteglo in other key European markets later this year and should file for U.S. approval within the next few months.

Several biotechs are developing gene-editing approaches to treat beta-thalassemia. The company with the most advanced gene-editing program is Sangamo Therapeutics (NASDAQ:SGMO). However, there are some worries about ST-400, the experimental gene therapy that Sangamo is developing with Sanofi. In December 2019, Sangamo announced preliminary results from an early stage clinical study that, while showing promise, raised safety concerns.

CRISPR Therapeutics (NASDAQ:CRSP) and its big partner, Vertex Pharmaceuticals (NASDAQ:VRTX), are evaluating CTX001 in early stage clinical studies for treating beta-thalassemia and SCD. CTX-001 uses CRISPR gene editing, a different method than the zinc-finger nuclease (ZFN) gene-editing approach that Sangamo uses. CRISPR Therapeutics and Vertex reported promising preliminary results in December 2019 from both of its clinical studies.

Editas Medicine (NASDAQ:EDIT) is also using CRISPR gene editing to target both beta-thalassemia and SCD. The biotech hasn't advanced its experimental therapy to a clinical study in humans yet but plans to file for FDA approval later in 2020 to begin clinical testing. Editas thinks that its gene-editing approach is superior to the ones being taken by CRISPR Therapeutics and Sangamo.

Trailing the pack is Syros Pharmaceuticals (NASDAQ:SYRS). In December, Syros and Global Blood Therapeuticssigned a deal to work together to develop drugs targeting beta-thalassemia and SCD based on Syros' gene control platform. Instead of trying to directly edit the gene mutations, Syros' gene control therapies attempt to control the expression of genes through genomic switches in other parts of DNA. The biotech hasn't said how soon it will be able to advance to clinical testing with its experimental drug.

There are a couple of big problems for investors with so many companies chasing after the same rare disease. First, it's impossible to know which experimental therapies will be successful. Second, if multiple drugs win regulatory approvals, the competition could be so fierce that no product is a huge moneymaker.

It's also important to know that several of the products being developed hold the potential to cure beta-thalassemia. These therapies could wipe out the opportunities for drugs that aren't curative.

One solution to this investor's dilemma is to avoid all of the biotech stocks that are focused on beta-thalassemia. However, that's like throwing the baby out with the bathwater. I think that a better alternative is to invest in the big drugmakers with beta-thalassemia programs.

Bristol-Myers Squibb already has one FDA approval under its belt for Reblozyl. BMS also owns 5.3% of CRISPR Therapeutics and is partnering with Editas on developing gene-editing therapies targeting cancer. Vertex is partnering with CRISPR Therapeutics and owns 10.2% of the small biotech. Both BMS and Vertex stand to win with their beta-thalassemia drugs but also have plenty of other growth drivers.

Excerpt from:
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease - The Motley Fool

Recommendation and review posted by Bethany Smith

The yellow monkeyflowers distinctive red spots serve as landing pads for bees and other pollinators, helping them access the sweet nectar inside. A new study reveals the genetic programming that creates these attractive patterns. (Image byPollyDotviaPixaBay)

February 24, 2020 - ByKara Manke- The intricate spotted patterns dappling the bright blooms of the monkeyflower plant may be a delight to humans, but they also serve a key function for the plant. These patterns act as bee landing pads, attracting nearby pollinators to the flower and signaling the best approach to access the sweet nectar inside.

They are like runway landing lights, helping the bees orient so they come in right side up instead of upside down, said Benjamin Blackman, assistant professor of plant and molecular biology at the University of California, Berkeley.

In a new paper, Blackman and his group at UC Berkeley, in collaboration with Yaowu Yuan and his group at the University of Connecticut, reveal for the first time the genetic programming that helps the monkeyflower and likely other patterned flowers achieve their spotted glory. Thestudywas published online today (Thursday, Feb. 20) in the journalCurrent Biology.

While we know a good deal about how hue is specified in flower petals whether it is red or orange or blue, for instance we dont know a lot about how those pigments are then painted into patterns on petals during development to give rise to these spots and stripes that are often critical for interacting with pollinators, Blackman said. Our lab, in collaboration with others, has developed the genetic tools to be able to identify the genes related to these patterns and perturb them so that we can confirm whats actually going on.

In the study, the research team used CRISPR-Cas9 gene editing to recreate the yellow monkeyflower patterns found in nature. On the left, a wild-type monkeyflower exhibits the typical spotted pattern. In the middle, a heterozygote with one normal RTO gene and one damaged RTO gene exhibits blotchier spots. And on the right, homozygote with two copies of the damaged RTO gene is all red, with no spots. (UC Berkeley photo by Srinidhi Holalu)

The positions of petals spots arent mapped out ahead of time, like submarines in a game of battleship, Blackman said. Instead, scientists have long theorized that they could come about through the workings of an activator-repressor system, following what is known as a reaction-diffusion model, in which an activator molecule stimulates a cell to produce the red-colored pigment that produces a spot. At the same time, a repressor molecule is expressed and sent to neighboring cells to instruct themnotto produce the red pigment.

The results are small, dispersed bunches of red cells surrounded by cells that keep the background yellow color.

By tweaking the parameters how strongly a cell turns on an inhibitor, how strongly the inhibitor can inhibit the activator, how quickly it moves between cells it can lead to big spots, small spots, striped patterns, really interesting periodic patterns, Blackman said.

In the study, UC Berkeley postdoctoral researcher Srinidhi Holalu and research associate Erin Patterson identified two natural varieties of the yellow monkeyflower one type with the typical red spots in the throat of the flower and a second type with an all-red throat appearing in multiple natural populations in California and Oregon, including at theUC Davis McLaughlin Reserve. In parallel, UConn postdoctoral researcher Baoqing Ding worked with a very similar plant with fully red-throated flowers found when surveying a population of Lewiss monkeyflower that had induced DNA mutations.

When the scientists presented bees in the lab with the two types of monkeyflowers, they preferred the red tongue variety to the spotted variety, though the red tongue variety is less common in nature. (UC Berkeley video by Erin Patterson and Anna Greenlee)

In a previous study, the Yuan lab had found that a gene called NEGAN (nectar guide anthocyanin) acts as an activator in the monkeyflower petals, signaling the cells to produce the red pigment. Through detailed genomic analysis in both monkeyflower species, the two groups were able to pinpoint that a gene called RTO, short for red tongue, acts as the inhibitor.

The red-throated forms of the monkeyflower have defective RTO inhibitor genes, resulting in a characteristic all-red throat, rather than red spots. To confirm their findings, Holalu used the CRISPR-Cas9 gene editing system to knock out the RTO gene in spotted variants of the flower. The result was flowers with a flashy red throat. Further experiments revealed how the functional form of the RTO protein moves to neighboring cells and represses NEGAN to prevent the spread of pigmentation beyond the local spots. This study is the first reported use of CRISPR-Cas9 editing to research the biology of monkeyflowers.

The team also collaborated with Michael Blinov at the UConn School of Medicine to develop a mathematical model to explain how different self-organized patterns might arise from this genetic system.

This work is the simplest demonstration of the reaction-diffusion theory of how patterns arise in biological systems, said Yaowu Yuan, associate professor of ecology and evolutionary biology at UConn. We are closer to understanding how these patterns arise throughout nature.

Monkeyflower plants with the RTO gene knocked out by CRISPR-Cas9 gene editing produce one big patch where all flowers exhibit a fully red throat, in contrast to wild fields where red-tongued flowers appear in small dispersed spots (UC Berkeley photo by Srinidhi Holalu)Source: UC Berkeley

Read more from the original source:
UC Professor On How The Monkeyflower Gets Its Spots - Sierra Sun Times

Recommendation and review posted by Bethany Smith

Todays businesses call for the highly focused, comprehensive and detail-oriented information about the market so that they get a clear idea about the market landscape. The Autologous Stem Cell And Non-Stem Cell Based Therapies market research report is generated with a combination of detailed industry insights, and use of latest tools and technology. The study of this market research report covers a market attractiveness analysis, wherein each segment is targeted based on its market size, growth rate, and general attractiveness. The Autologous Stem Cell And Non-Stem Cell Based Therapies market research report plays a key role in developing the strategies for sales, advertising, marketing, and promotion.

TheGlobalAutologous Stem Cell and Non-Stem Cell Based Therapies Marketis expected to reach USD113.04 billion by 2025, from USD 87.59 billion in 2017 growing at a CAGR of 3.7% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2015 & 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

For In depth Information Get Sample Copy of this Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

Some of the major players operating in the global autologous stem cell and non-stem cell based therapies market areAntria (Cro), Bioheart, Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Neostem, Opexa Therapeutics, Orgenesis, Regenexx, Regeneus, Tengion, Tigenix, Virxsys and many more.

Market Definition:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

In autologous stem-cell transplantation persons own undifferentiated cells or stem cells are collected and transplanted back to the person after intensive therapy. These therapies are performed by means of hematopoietic stem cells, in some of the cases cardiac cells are used to fix the damages caused due to heart attacks. The autologous stem cell and non-stem cell based therapies are used in the treatment of various diseases such as neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, infectious disease.

According to World Health Organization (WHO), cardiovascular disease (CVD) causes more than half of all deaths across the European Region. The disease leads to death or frequently it is caused by AIDS, tuberculosis and malaria combined in Europe. With the prevalence of cancer and diabetes in all age groups globally the need of steam cell based therapies is increasing, according to article published by the US National Library of Medicine National Institutes of Health, it was reported that around 382 million people had diabetes in 2013 and the number is growing at alarming rate which has increased the need to improve treatment and therapies regarding the diseases.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

Market Segmentation:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Competitive Analysis:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The global autologous stem cell and non-stem cell based therapies market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of autologous stem cell and non-stem cell based therapies market for global, Europe, North America, Asia Pacific and South America.

Major Autologous Stem Cell and Non-Stem Cell Based Therapies Market Drivers and Restraints:

Introduction of novel autologous stem cell based therapies in regenerative medicine

Reduction in transplant associated risks

Prevalence of cancer and diabetes in all age groups

High cost of autologous cellular therapies

Lack of skilled professionals

Reasons to Purchase this Report

Customization of the Report:

Speak to Author of the report @https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Read more here:
Autologous Stem Cell And Non-Stem Cell Based Therapies Market 2020-2025 to Set New Growth Cycle || Leading Players Fibrocell, Genesis Biopharma,...

Recommendation and review posted by Bethany Smith

Houston, TX A variety of science investigations, along with supplies and equipment, launch to the International Space Station on the 20th SpaceX commercial resupply services mission.

The Dragon cargo spacecraft is scheduled to leave Earth March 2nd from Space Launch Complex 40 at Cape Canaveral Air Force Station in Florida. Its cargo includes research on particle foam manufacturing, water droplet formation, the human intestine and other cutting-edge investigations.

Airbus workers unpack the Bartolomeo platform at NASAs Kennedy Space Center in Florida in preparation for its launch to the International Space Station. The platform, manufactured by Airbus Defence and Space, hosts multiple external payloads in low-Earth orbit. (NASA)

The space station, now in its 20th year of continuous human presence, provides opportunities for research by government agencies, private industry, and academic and research institutions.

Such research supports Artemis, NASAs missions to the Moon and Mars, and leads to new technologies, medical treatments and products that improve life on Earth.

Particle foam molding is a manufacturing process that blows thousands of pellets into a mold where they fuse together. The shoe company Adidas uses this process to make performance midsoles, the layer between the sole of a shoe and the insole under your foot, for its products.

The BOOST Orbital Operations on Spheroid Tesellation (Adidas BOOST) investigation looks at how multiple types of pellets behave in this molding process. Using one type of pellet creates a foam with the same properties throughout the sole component. Using multiple pellet types can allow engineers to change mechanical properties and optimize shoe performance and comfort. Removing gravity from the process enables a closer look at pellet motion and location during the process.

Results of this investigation could demonstrate the benefits of microgravity research for manufacturing methods, contributing to increased commercial use of the space station. New processes for particle foam molding could benefit a variety of other industries, including packaging and cushioning materials.

The Bartolomeo facility, created by ESA (European Space Agency) and Airbus, attaches to the exterior of the European Columbus Module. Designed to provide new scientific opportunities on the outside of the space station for commercial and institutional users, the facility offers unobstructed views both toward Earth and into space.

Airbus is collaborating with the United Nations Office of Outer Space Affairs to offer UN Member States the opportunity to fly a payload on Bartolomeo. Developing countries are particularly encouraged to participate, and the mission is devoted to addressing the UNs Sustainable Development Goals. Bartolomeo is named for the younger brother of Christopher Columbus.

Droplet Formation Studies in Microgravity (Droplet Formation Study) evaluates water droplet formation and water flow of Delta Faucets H2Okinetic showerhead technology. Reduced flow rates in shower devices conserve water, but also can reduce their effectiveness.

That can cause people to take longer showers, undermining the goal of using less water. Gravitys full effects on the formation of water droplets are unknown, and research in microgravity could help improve the technology, creating better performance and improved user experience while conserving water and energy.

Insight gained from this investigation also has potential applications in various uses of fluids on spacecraft, from human consumption of liquids to waste management and use of fluids for cooling and as propellants.

Human intestine cells forming microvilli inside Emulates Intestine-Chip. (Emulate)

Organ-Chips as a Platform for Studying Effects of Space on Human Enteric Physiology (Gut on Chip) examines the effect of microgravity and other space-related stress factors on biotechnology company Emulates human innervated Intestine-Chip (hiIC). This Organ-Chip device enables the study of organ physiology and diseases in a laboratory setting. It allows for automated maintenance, including imaging, sampling, and storage on orbit and data downlink for molecular analysis on Earth.

A better understanding of how microgravity and other potential space travel stressors affect intestine immune cells and susceptibility to infection could help protect astronaut health on future long-term missions. It also could help identify the mechanisms that underlie development of intestinal diseases and possible targets for therapies to treat them on Earth.

Self-assembly and self-replication of materials and devices could enable 3D printing of replacement parts and repair facilities on future long-duration space voyages. Better design and assembly of structures in microgravity also could benefit a variety of fields on Earth, from medicine to electronics.

Called self-assembled colloidal structures, these are vital to the design of advanced optical materials, but control of particle density and behavior is especially important for their use in 3D printing. Microgravity provides insight into the relationships among particle shape, crystal symmetry, density and other characteristics.

Functional structures based on colloids could lead to new devices for chemical energy, communication, and photonics.

The Multi-use Variable-g Platform (MVP) used for the MVP Cell-03 experiment, shown with the MVP door removed and two carousels inside. (Techshot Inc.)

Generation of Cardiomyocytes From Human Induced Pluripotent Stem Cell-derived Cardiac Progenitors Expanded in Microgravity (MVP Cell-03) examines whether microgravity increases the production of heart cells from human-induced pluripotent stem cells (hiPSCs).

HiPSCs are adult cells genetically reprogrammed back into an embryonic-like pluripotent state, which means they can give rise to several different types of cells. This makes them capable of providing an unlimited source of human cells for research or therapeutic purposes.

For MVP Cell-03, scientists induce the stem cells to generate heart precursor cells, then culture those cells on the space station for analysis and comparison with cultures grown on Earth.

These heart cells or cardiomyocytes (CMs) could help treat cardiac abnormalities caused by spaceflight. In addition, scientists could use them to replenish cells damaged or lost due to cardiac disease on Earth and for cell therapy, disease modeling and drug development. Human cardiac tissues damaged by disease cannot repair themselves, and loss of CMs contributes to eventual heart failure and death.

These are just a few of the hundreds of investigations currently aboard the orbiting laboratory. For daily updates, follow @ISS_Research, Space Station Research and Technology News or our Facebook. Follow the ISS National Lab for information on its sponsored investigations. For opportunities to see the space station pass over your town, check out Spot the Station.

Related Stories

Link:
NASA to send equipment to International Space Station to research Improving Shoes, Showers, 3D Printing - Clarksville Online

Recommendation and review posted by Bethany Smith

In a couple of weeks, SpaceX will be launching a Dragon cargo spacecraft bound for the International Space Station (ISS), carrying not only supplies for the astronauts but also a range of scientific equipment and research technology. The cargo includes tools for researching everything from growing human heart cells to making more comfortable sneakers.

One of the largest additions to the ISS will be the Bartolomeo facility, a European Space Agency project to provide more room for scientific experiments by attaching to the outside of the space station. Potential uses for the extended space include Earth observation, robotics, material science, and astrophysics, according to NASA.

Other projects include one by Adidas to test out its molding process in which thousands of pellets are blown together until they fuse, creating a midsole for shoes to make them more cushioned for high-performance athletes. Theres also a study into how water droplets form in low gravity which could help reduce the amount of water used by showers here on Earth, assisting the important project of water conservation. And theres a project to test improvements in 3D printing which could be used to print spare parts and repair tools for future space voyages.

Finally, there are also two biomedical experiments being taken to the ISS. One will look at how microgravity affects biotechnology like the Organ Chip which simulates the responses of human tissue on a small chip. And the other will investigate whether it is possible to grow human heart cells from stem cells in microgravity. The researchers believe the development of these heart cells could eventually be used to treat cardiac problems here on Earth, especially among children as their cardiac issues are particularly hard to treat.

The mission is scheduled to launch at 10:45 p.m. PT on Sunday, March 1, from Space Launch Complex 40 at Cape Canaveral Air Force Station in Florida. This will be the 20th mission as part of NASAs Commercial Resupply Services contract, in which private companies like SpaceX and Boeing take over some duties for delivering supplies to the ISS.

In the future, SpaceX will be taking a larger part in ISS operations as well. It will be delivering astronauts to and from the space station as part of NASAs Commercial Crew program, using its Crew Dragon capsule. The first manned Crew Dragon mission is targeted for May 7.

Link:
Here are all the science projects that SpaceX will deliver to the ISS - Digital Trends

Recommendation and review posted by Bethany Smith

The military wants to experiment with commercial satellites from OneWeb and SpaceXs Starlink mega-constellations to keep war fighters connected in the Arctic, but it will need extra funding to do so.

Those companies aim to provide internet access via proliferated constellations made up of thousands of small satellites in low earth orbit. The military has been keen on leveraging this growing commercial capability, and the Air Force has awarded contracts to test how the satellite broadband service can be used by war fighters.

Now the commander of the United States Northern Command and the North American Aerospace Defense Command is expressing interest in using these commercial space internet services to provide communications in the polar regions, where satellite communications have traditionally been more limited. Gen. Thomas OShaughnessy is seeking $130 million for the effort, which he has listed as his number one unfunded priority for fiscal year 2021.

In a Feb. 11 letter to Congressional defense committees, OShaughnessy explained the money will be used for polar communications experiments and the fielding of prototype terminals capable of utilizing Starlink and OneWeb satellites. Additionally, the commander expressed hope that these experiments will incentivize further commercial investments in satellite communications and internet in the Arctic.

Full coverage will require an additional $110 million in fiscal year 2022, the document notes.

OneWeb leaders have said they expect to have 24 hour coverage in the Arctic by early 2021.

The request for polar communications funding was one of four unfunded priorities the commander sent to Congress. That funding is focused on my most pressing needs of increasing our domain awareness and establishing a layered homeland defense architecture.

The full list includes $20 million for a sentry radar, $5 million for Persistent Elevated Intelligence, Surveillance and Reconnaissance and $31 million for the COBRA Dane Service Life Extension Program.

Sentry radars are capable of mid-range detection, tracking and positive identification of low radar cross-section targets, including cruise missiles and drones, and the commander wants it to provide point defense of critical infrastructure and force deployment areas. Meanwhile, the $5 million for Persistent Elevated ISR will be used to develop and prototype a radar capability for point defense locations within the continental United States.

COBRA Dane is a phased array radar based in Alaska that was initially deployed in 1977. The radar has since been updated and integrated into the Ballistic Missile Defense System, although it continues to provide intelligence and space situational awareness. Due to delays in bringing replacement radars in Hawaii and the Pacific online, COBRA Dane will need to continue operations past the end of its expected service life in 2030. The commander is seeking $31 million to replace the transmitter group, travelling wave tubes and a mainframe computer.

Read the rest here:
Will SpaceX and OneWeb help the military stay connected in the Arctic? - C4ISRNet

Recommendation and review posted by Bethany Smith

The false alarm earlier this year at Ontarios Pickering nuclear power plant, and the subsequent revelation that Doug Fords Conservative government intends to further extend the life of the already aged plant, has put the issue of the governments approach to energy and environmental matters back on the political agenda.

The news that the costs of keeping electricity rates in Ontario artificially low have ballooned to $5.6 billion a year has further reinforced the need for a serious reconsideration of the provinces approach to energy matters.

Ontario currently has a surplus of electricity. That will change significantly over the next few years. The Pickering plant east of Toronto will be retired by 2024. Multiple reactors at the Bruce and Darlington nuclear facilities will be taken out of service for refurbishment between now and the early 2030s.

The provinces approach to making up these shortfalls seems likely to rely heavily on the large approximately 10,000 megawatts fleet of natural gas-fired generating facilities constructed since the early 2000s. The result could be the erosion of a significant (30 to 40 per cent) portion of the reductions in emissions of greenhouse gases and smog precursors obtained through the phaseout of coal-fired generation, completed in 2014.

The ongoing life extension of the Pickering nuclear facility its now operating beyond end-of-life after its original operating licence expired in August 2018 raises further questions about whether there are different, safer and more sustainable paths available to the province.

A recent study completed for the Ontario Independent Electricity System Operator suggested that future electricity demand could be reduced by 25 per cent, and natural gas consumption reduced by 31 per cent, over the next 20 years through efficiency measures. Other analyses suggest that potential savings could be substantially greater.

Energy-efficiency initiatives can encompass upgrading or replacing buildings and energy-hogging appliances with more efficient versions, behaviour changes, self-generation through actions like the installation of rooftop solar panels and better managing the timing of energy consumption.

Energy-efficiency initiatives are consistently identified as the lowest impact and most cost-effective means of meeting energy needs, while strengthening the resiliency of energy systems.

Energy-efficiency improvements could reduce the need to run natural gas-fired generation, and allow for an earlier retirement of the Pickering plant.

Energy-efficiency gains, particularly those that help to reduce the need for electricity during periods of high demand, could also play a significant role in making the best use of Ontarios substantial renewable energy resources (4,500 megawatt wind and 450 megawatt solar photovoltaic, or PV) that were added to the provinces electricity system between 2005 and 2018.

Read more: Ontario can phase out nuclear and avoid increased carbon emissions

Until last year, the province had a relatively comprehensive strategy of electricity energy efficiency. But the 2014-20 Conservation First framework was, with a few exceptions, terminated by the Ford government in March 2019 as part of its determination to reduce electricity costs in the short term.

While largely effective, Conservation First suffered from significant gaps in terms of overall program co-ordination.

The lack of integration with natural gas conservation initiatives was consistently identified as a major shortfall. The use of natural gas to heat buildings is widely identified as one of two key areas of GHG emission growth in Ontario, the other being transportation. The Ford governments December 2018 Made-in-Ontario Environment Plan made reference to a major expansion of natural gas conservation targets. But theres been no follow-up since.

The existing arrangements around natural gas conservation have survived so far, and are generally regarded as successful. But far more ambitious targets are needed to significantly affect the provinces greenhouse gas emissions.

Ontario seems to have abandoned energy efficiency as an element of its energy and climate change plans. Other provinces, including British Columbia, Qubec and Nova Scotia, as well as many U.S. states, despite disruptions, have continued to move forward with comprehensive energy-efficiency strategies. Even Jason Kenneys Alberta has stayed on course, for now.

There are several major steps Ontario could take to get back on track. The province should start by establishing a new provincial agency call it Energy Efficiency Ontario with a mandate to develop a comprehensive, integrative, cost-effective energy-efficiency strategy for Ontario.

An important step would be to re-engage municipally owned local electricity distribution companies that played a significant and largely successful role in Conservation First before it was terminated by the Ford government.

Enbridge could continue to deliver enhanced conservation initiatives to natural gas consumers. At the same time, electricity and natural gas conservation needs to be better integrated into a single service so that customers dont have to deal with multiple utilities and programs.

The most stable and successful funding model for energy-efficiency initiatives in North America is to embed costs in electricity and natural gas rates. This should be the case in Ontario as well.

The short-term savings to consumers from the Ford governments removal of energy-efficiency costs from electricity charges amounted to less than $10 per person per year. In contrast, the long-term benefits in terms of reduced electricity costs for consumers were estimated in the range of $25 per person per year according to the Ontario Environmentalism Commissioners 2019 report.

Enbridge and the provinces electricity system operator should follow the model of leading jurisdictions like California. They should be required to show their commitment to cost-effective and achievable energy-efficiency opportunities as a condition of rate and capital investment approval by the Ontario Energy Board on an ongoing basis.

The situation in Ontario is complicated by the lack of any meaningful overall energy planning framework, particularly with respect to electricity. That point was highlighted again by the governments unexpected and unexamined decision to further extend the life of the Pickering nuclear plant.

An energy-efficiency strategy that ensures Ontario pursues its lowest-risk and lowest-cost options first would be a good place to start.

Original post:
Energy conservation needs to take centre stage in Ontario - The Conversation CA

Recommendation and review posted by Bethany Smith

Teaming up with Welding Research Institute, the Indian Institute of Metals - Tiruchi Chapter, on Monday, oriented participants of E-LIFE 2020, a workshop on Engineering and Life Extension Aspects of Boilers, on the way forward to address challenges in operating ultra-super critical power boilers, in the areas of stricter environmental norms, green house gas effects, tariff, and disposal of wastes.

Resource persons comprising senior officials of BHEL engaged participants comprising users, original equipment manufacturers, consultants, faculty, researchers and students in sessions on mechanical design of power boilers, thermal design of surfaces for pressure parts in power boilers, atmospheric fluidised bed combustion, circulating fluidised-bed combustion technology, and computational fluid dynamics.

R. Easwaran, former Chairman, IIM-TRY inaugurated the programme in the presence of T.A. Daniel Sahayaraj, Chairman.

The focus of the second day programme on Tuesday will be on water chemistry and life extension in boilers, N. Rajasekaran, Vice-Chairman, IIM, Tiruchi Chapter, and Deputy General Manager, BHEL, Tiruchi, said.

In life extension programme, the participants will be apprised about the methodology of replacing pressure parts that are subjected to corrosion and erosion, to extend the life of the power plant for another 15 years, the organisers said.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Read this article:
Emphasis on extending life of boilers - The Hindu

Recommendation and review posted by Bethany Smith

Klada is the largest gold mine in Turkey. (Image courtesy of Eldorado Gold.)

Following last weeks release of year-end results and five-year guidance fromEldorado Gold (TSE: ELD), the intermediate-producers stock soared over 30% in one day and breached eight-year highs.

Eldorado also announced a 15-year mine life at its Kisladag open pit operation in Turkey after completing long-cycle heap leach tests and replacing the tertiary crushing circuit with a high-pressure grinding roll (HPGR) circuit.

Kisladag has been a cornerstone asset of Eldorado for over a decade, producing over three million ounces of gold and generating significant value for all stakeholders during that period, George Burns, the companys president and CEO said in a release.

Following the resumption of full operations last spring, and the significant work and testing undertaken by the Eldorado team over the past 18 months, we are pleased to announce a mine life extension at Kisladag that puts this asset back in the core of our portfolio.

This year, the company expects to produce 520,000 ounces to 550,000 ounces

This year, the company expects to produce 520,000 ounces to 550,000 ounces at AISCs of $850 to $950 per ounce. Over the next five years, it anticipates production from its four operating mines to average over 450,000 ounces.

Last year, the Eldorados gold output was at 395,331 ounces at AISCs of $1,034 per ounce with $150.6 million in cash flow generated from operating activities, before changes in working capital.

Increased leach time with HPGR appears to increase heap leach recoveries at Kisladag to 56% with an updated average annual gold production expected at 160,000 ounces at AISCs of $800 to $850 per ounce.

Over the next five years, Kisladag and the underground Lamaque mine in Quebec, which declared commercial production last March, appear to be the largest gold contributors.

Eldorado also operates the underground Efemcukuru mine in western Turkey and the Olympias gold-silver-lead-zinc mine in northern Greece.

In addition to its gold-producing operations, in Greece, Eldorado holds the Skouries and Perama Hill projects which are currently on care and maintenance: Skouries was placed on care and maintenance at the end of 2018 due to ongoing permitting delays.

In January, Eldorado announcedthe discovery of the Ormaque zone at its Lamaque operation.

(This story first appeared at the Canadian Mining Journal)

View post:
Eldorado revamps Kisladag and expects over 450000 ounces annually - MINING.com

Recommendation and review posted by Bethany Smith

Dr Sahibzada, the Director of Islamic Center and Imam of the Mosque of Grand Rapids, responds:

God has Absolute Knowledge and Absolute Authority of power over everything. He has created life and death to determine who does righteous deeds. No one knows lifes age, where, when someone is going to die and how. All is in Gods hands. When death comes it will never be delayed for a fraction of moment.

Humans think that they are prolonging life, but it is fixed term and God has its knowledge. No one can save oneself from death and there is no cure for death. Every soul will taste death. Final moment of humans life is determined.

Humans perceive they can prolong life, but it is not in their hands. Life must traverse certain passage to its end in each individual case. God has determined end time and He is the only authority to prolong or shorten it.

God has bestowed limited options to humankind to put all efforts to cure lifes intricacies in accordance to capacity level. Results will be at par with efforts one has put in, but the end time approaches and all efforts also come to an end.

The Reverend Colleen Squires, minister atAll Souls Community Church of West Michigan, a Unitarian Universalist Congregation, responds:

Medicine seems to be always advancing the cutting edge, and it is often outpacing religious, ethical and moral beliefs.Unitarian Universalists believe all medical decisions are best made between the patient and their doctor.We do not believe in prolonging life at all cost and I think most of us would reject extraordinary measures merely to keep someone alive.We value the quality of life and we value our right to make our own end of life decisions.

Fred Stella, the Pracharak (Outreach Minister) for the West Michigan Hindu Temple, responds:

Hinduism rejects the idea of a human-like judge who makes seemingly arbitrary decisions as to things such as our death. Our life span is decided by any number of factors, most of them karmic. By that, I mean, for the most part, our past actions in this lifetime. This includes our diet, exercise habits, connection to support systems, education, wealth, etc. Obviously, there are factors that are beyond our control such as genetics, environmental pollution, civil strife, war, and so forth. When we change our present actions we can change our future. Therefore, it is not a stretch to say that a person who seems to be close to death from a heart attack might alter that outcome by having surgery. This not much different from a person whose life might be in danger due to obesity starting to moderate his or her diet and adding physical activity to the daily routine. By doing so life may be extended.

To be clear, I am not advocating life extension for its own sake. These are evaluations that must be judiciously made by individuals and their families. In these times, when medical machinery can keep a person alive long after they have lost any semblance of their former life, I consider it a moral imperative for each adult to make their wishes known well in advance of the need for any decision.

Rev. Ray Lanning, a retired minister of the Reformed Presbyterian Church of North America, responds:

God has indeed decreed for every one of us when and how we shall die: It is appointed unto men once to die, but after this the judgment (Hebrews 9:27). But such things are not known to us. That means that we need to consult Gods Word and pray for guidance when we address end of life questions, such as the use of heroic or extraordinary measures to prolong the life of our bodies.

Those who are prepared to die and appear before the judgment seat of Christ have no reason to cling to this earthly life at all costs. The Apostle Paul declared, For me to live is Christ, and to die is gain (Philippians 1:21). He felt himself in a strait betwixt two, having a desire to depart, and to be with Christ; which is far better: nevertheless to abide in the flesh is more needful for you(v. 23, 24), that is, the Christians whom he had led to faith by his preaching. He was convinced that God still had work for him to do on earth.

So what do you have to gain by these extraordinary measures? What purpose will it serve to prolong your days on earth? Nothing in Gods Word requires or forbids you to use such means. What matters most is to live and die as a Christian, as one reconciled to God by the death of His Son, and an heir to everlasting life.

This column answers questions of Ethics and Religion by submitting them to a multi-faith panel of spiritual leaders in the Grand Rapids area. Wed love to hear about the ordinary ethical questions that come up in the course of your day as well as any questions of religion that youve wondered about. Tell us how you resolved an ethical dilemma and see how members of the Ethics and Religion Talk panel would have handled the same situation. Please send your questions to[emailprotected].

The Rapidian, a program of the 501(c)3 nonprofit Community Media Center, relies on the communitys support to help cover the cost of training reporters and publishing content.

We need your help.

If each of our readers and content creators who values this community platform help support its creation and maintenance, The Rapidian can continue to educate and facilitate a conversation around issues for years to come.

Please support The Rapidian and make a contribution today.

Excerpt from:
Ethics and Religion Talk: Does Medical Intervention Subvert God's Will? - The Rapidian

Recommendation and review posted by Bethany Smith

The Global Antioxidant Supplement Market report study includes an elaborative summary of the Antioxidant Supplement market that provides in-depth knowledge of various different segmentations. Antioxidant Supplement Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Antioxidant Supplement Market. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps. Antioxidant Supplement delivers pin point analysis of varying competition dynamics and keeps ahead of Antioxidant Supplement competitors such as NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension.

The report entitled Global Antioxidant Supplement Market 2019 focuses on edging and imitate the key affecting components for the expansion of the market. It further proposes an intensive study of the market stature (revenue), market share, key market segments, distinct geographic regions, main market players, and prime industry trends. The point of this report is to depict the expected market patterns and revenue forecast for the global Antioxidant Supplement market for the following five years.

Get a piece of exclusive information to get Product Specifications

The report global Antioxidant Supplement market records the essential market events comprehensive of product launches, mergers and acquisitions, technological advancement, and the brand new business outlines favored by driving business sector players. Worldwide Antioxidant Supplement Market Report additionally covers every single part of the business and the conspicuous market players present in particular countries examine the new advancement plans, advertise position, which will help in settling on essential business choices.

Key players featuring in Antioxidant Supplement market:

Global Antioxidant Supplement report covers particular aspects of the market including the product classification, product details, scope of uses and major geographical producing regions. The key districts overcast in Antioxidant Supplement report are the countries present in North America, Europe, APAC, South America, Middle East, and Africa.

Inquiry for Buying Report: https://www.marketresearchstore.com/report/global-antioxidant-supplement-market-status-trend-report-2013-273749#InquiryForBuying

1.USA2.Europe3.Japan4.China5.India6.Southeast Asia

furthermore, the aspect that triggers and restricts the growth of the global Antioxidant Supplement industry is specified and simplify in depth in this research study. It helps experts in taking significant business choices to publicize their business. The study additionally examines regions having potentialities for future market development. It also gives data about developing markets, beneficial markets, static markets, declining markets, soaked markets or develop advertises along with development benefits.

1. The Outlook of the Antioxidant Supplement Industry2. Global Market Competition Landscape3. Global Antioxidant Supplement Market share4. Supply Chain Analysis5. Company Profiles6. Globalization & Trade7. Distributors and Customers8. Import, Export, Consumption and Consumption Value by Major Countries9. Global Antioxidant Supplement Market Forecast to 202410. Key success factors and Market Overview

In the end, the Antioxidant Supplement market collecting historical and recent data from various authentic resources and depending on all the factors and trends, the report presents a figurative estimate of the future market condition, along with compound annual growth rate (CAGR).

Read More Post:http://www.marketsnresearch.com/global-oilfield-stimulation-chemicals-market-report-2018-industry.html

View post:
Global Antioxidant Supplement Market Analysis 2020 2025 With Top Companies of Industry like NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas -...

Recommendation and review posted by Bethany Smith

Location technology is "kind of a coin toss." The FCC has given carriers until 2021 to make sure transmission locations are within 50 yards 80% of the time. Public health news is on USPS work-related injuries, a biomedical research contest, suicide-crisis centers, prostate cancer, a lucky fall, perinatal stroke, birthing plans, disparity in birth outcomes, medical clowns, chocolate's appeal, friendship and health, childhood prosthetics, and healthy beverages, as well.

The Washington Post:College Student Yeming Shen Died Of Flu In Troy, N.Y., After 911 Couldnt Track His Location.Yeming Shen called 911 on Feb. 10. He was alone in his Troy, N.Y., apartment, dying of the flu. But the garbled call was unintelligible to the operators, and police couldnt pinpoint the phones location. For 45 minutes after Shen called 911, five police officers, three firefighters and a police dog searched in vain for the student. All they had was a general area encompassing two apartment buildings. They eventually gave up without finding Shen. Six hours later, the Rensselaer Polytechnic Institute students roommate discovered his body, the Times Union first reported. (Kornfield, 2/22)

ProPublica:The Postal Service Fired Thousands Of Workers For Getting Injured While Delivering And Processing Your MailOne night in 2009, Madelaine Sattlefield lifted an 80-pound tray of letters carefully sorted by Missouri ZIP code. She had done this task thousands of times in nine years, but on this night, her arm seared with pain and went limp by her side. The tray crashed and sent envelopes cascading around her. She could barely move but immediately worried about what an injury might mean for her job. Anxiety had kicked in. I was like, what are they going to say, what are they going to do? Sattlefield said. (Jameel, 2/24)

Stat:Here Are The Contenders For STAT Madness 2020ADNA microscope. A gene therapy for bubble boy disease. The restoration of cellular activity in pig brains four hours after death. Nano-robots that might clean teeth better than flossing. These are just some of the 64 important discoveries and inventions included in this years STAT Madness, a bracket-style competition to honor the best biomedical research published in 2019. (2/24)

Stateline:As Suicide Rates Climb, Crisis Centers ExpandNationwide, most people picked up by police for a misdemeanor while in a psychiatric crisis are taken directly to a hospital emergency department, where they typically are held for hours or days, often involuntarily confined, according to emergency department surveys. Many are charged and held in jail with no mental health professional to talk to and no access to psychiatric medicines. The same goes for people with drug addiction. In the past five years, thats become a rarity in Arizona. As in other parts of the country, Arizonas crisis centers are open 24 hours, seven days a week, and everyone is accepted, regardless of whether they have health insurance. (Vestal, 2/24)

The New York Times:Debating The Value Of PSA Prostate ScreeningWeve long been schooled on the lifesaving value of early detection of a potentially deadly cancer. So when a simple blood test was introduced in 1994 that could detect the possible presence of prostate cancer, the second leading cause of cancer deaths among American men, its not hard to understand why it quickly became hugely popular. (Brody, 2/24)

The Washington Post:Synovial Chondromatosis: A Hard Fall Unmasked This Unusual And Painful ConditionIf she hadnt tripped over her neighbors dog, causing her to miss the step down into a sunken living room where she landed squarely on her left hip, Lynda Holland still might not know what was wrong. Holland scrambled to her feet, shaken and grateful she hadnt been injured: Her puffy down coat had cushioned her fall onto the hardwood floor. Then she realized the pain that had dominated her life for the previous six years had suddenly diminished. (Boodman, 2/22)

The Washington Post:Perinatal Stroke: Some Infants In Utero Lose Blood Supply To Their Brains, Causing Physical Or Cognitive Problems Later. New Therapies May Help.Nicole Dodds first noticed her son, Rowan, was having trouble using the right side of his body when he was about 6 months old. Babies typically use both hands to pick up toys and lift their chest off the floor at that age, but Rowan was mostly using his left arm and hand, keeping his right hand balled in a fist. That started a string of doctor visits. Around Rowans first birthday, doctors did an MRI and diagnosed his one-sided weakness as hemiplegia, probably caused by a stroke he sustained in utero. This surprised Dodds, since as far as she knew shed had a totally normal pregnancy and birth. (Witman, 2/22)

NBC News:She Wanted A 'Freebirth' With No Doctors. Online Groups Convinced Her It Would Be OK.For women who havent gone into labor by 42 weeks, just about every medical and birth professional recommends induction a jump-start to labor from medicines that ripen the cervix or contract the uterus. But Judith, an artist and freethinker who believes in all that hippy jazz, had a different kind of birth plan one that dismissed medical recommendations and relied on nature and intuition, that rejected a sterile hospital for a warm pool in her own home and that avoided doctors and midwives. Instead, Judith wanted to be with only her husband and her closest friend, a plan known as freebirth, or unassisted birth, by the tiny subculture of women who practice it. (Zadrozny, 2/21)

GMA:Stunning Photos Of Black Women Raises Awareness About Disparity In Birth OutcomesIt was about five years ago when Dallas-Fort Worth photographer Elaine Baca photographed her first birth. Until then, she had been primarily working weddings... According to the Centers for Disease Control and Prevention, the risk of pregnancy-related deaths for black women is 3 to 4 times higher than those of white women."It's important for people to see and understand that black women and babies who are dying in childbirth are not just statistics put out by the CDC," Baca told "GMA." (Brown, 2/24)

The Washington Post:Clowns Can Help Treatment In HospitalsMedicine is serious business. But for a growing number of patients, a trip to the hospital may include a laugh with a clown. Medical clowns health-care workers who dress up and act like clowns to help make medical procedures and hospital stays less stressful can be found around the world. The growing field relies on the age-old performance art of clowning to help lift the strain that can pervade the treatment of all-too-serious health concerns. (Blakemore, 2/22)

NBC News:Why Chocolate Is So Addicting And How To Tap Into The Health BenefitsThough chocolate is typically divided into three categories: dark, milk and white, the latter two really should just be called highly-processed interpretations of chocolate, because thats basically what they are. And its the processed sugars, salts and fats that make these varieties so tasty which is also what makes them so addictive. (Spector, 2/23)

CNN:Want To Lose More Weight? Intensive Therapy From Dietitians Can Help Older Adults, Study FindsOlder adults may have better success at losing weight if they do it with the help of intensive behavioral therapy from dietitians, a new study suggests. Intensive behavioral therapy for obesity, or IBTO, is a customized treatment that helps people change their eating and exercise behaviors through a series of one-on-one counseling sessions. (Rogers, 2/21)

NPR:How Good Friends Are Good For Your HealthLydia Denworth wants you to make more time for your friends. We don't fully appreciate our friendships, says the science writer and author of the new book Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond. If we did, we'd take cultivating those intimate bonds as seriously as working out or eating well. Because, she writes, a new field of science is revealing that social connections play a vital role in our health. (Renken, 2/22)

The Washington Post:Children Who Need Prosthetics Can Quickly Outgrow Them And Insurers Are Reluctant To Pay For Running Legs. Nonprofits Are Helping Out.Faith Trznadel was born without a tibia bone, and when she was 10months old, doctors had to amputate her lower leg. The hardest part is the staring, the snickering, said Faiths mother, Sheila Trznadel, about how other people treated her daughter. One message to get across to people is its okay to ask questions. ... Its better to ask questions than just stare. [Its] getting rid of that stigma. (Furby, 2/23)

The New York Times:Milk And Juice Are Not As Needed As You Might ThinkIs there such a thing as a healthful beverage? In truth, theres not much of a health case to drink any beverage other than water after the age of 2 despite the marketing and advertising you might have seen on the benefits of things like dairy milk, plant-based milks, juices and more. (Carroll, 2/24)

Excerpt from:
Dying Of Flu, College Student Used Cellphone To Call 911. He Died When Police Couldn't Find His Location. - Kaiser Health News

Recommendation and review posted by Bethany Smith

By Jodi Helmer

When Heidi E. Godoy, D.O., gynecologic oncologist, sees new ovarian cancer patients for the first time, she starts preparing them for the likelihood their cancer will return.

Dr. Heidi E. Godoy, gynecologic oncologist

For those unfamiliar with the disease, Godoys early focus on recurrence may seem premature. But she believes that being upfront about the realities of ovarian cancer is as important as discussing the initial treatment, which is typically surgery followed by platinum-based chemotherapy.

Ovarian cancer is difficult to diagnose, increasing the odds that it wont be discovered until it reaches an advanced stage. And in 85% of late-stage ovarian cancer cases, the disease recurs, according to research published in the International Journal of Surgical Oncology.1

One of the first conversations I have with patients outlines the relapse that often happens with ovarian cancer, said Godoy, who works in private practice in New York State and is affiliated with several hospitals there. I dont want it to be a surprise if the cancer returns.

Godoy also makes it a point to reassure women living with ovarian cancer that she will be with them throughout their cancer journey. Gynecologic oncologists, she explained, generally provide complete care, from diagnosis to surgery, for cancers affecting the ovaries, uterus, cervix, vulva and vagina. Holistic care is one of the reasons she pursued the subspecialty.

When I was going through medical school, I wanted a subspecialty that provided a lot of continuity of care, Godoy recalled. In gynecologic oncology, you develop such personalized, deep relationships with your patients.

Expert, Empathetic Care

For women living with ovarian cancer, receiving treatment from a gynecologic oncologist can simplify care and provide a sense of familiarity with their treatment teams. Research published in Frontiers In Oncology2 in 2015 shows that the highly-trained medical professionals also provide positive clinical outcomes.

Gynecologic oncologists perform complex procedures such as surgical debulkinga tumor-removal procedure that often affects other organsto remove the entire tumor and improve the prognosis. They are among the only specialists that perform surgical debulking, Godoy said. While surgery and chemotherapy are well-known components of treatment plans, maintenance therapies have become meaningful options for doctors in recent years.

Ovarian cancer patients who have a response to platinum-based chemotherapy in the recurrent setting are candidates for PARP inhibitors, one of those being niraparib or ZEJULA, Godoy explained.

Those candidatespatients who recur after a first-line treatment and receive a second line of platinum-based chemotherapyreally need to have that conversation about starting maintenance therapy, she continued.

The current approach of watch-and-wait, where we take them off their chemotherapy or their cytotoxic therapy and just watch and wait to see if the cancer returns, is no longer the only option, Godoy said. Maintenance therapy has changed the paradigm of watching and waiting to see if the cancer returns.

ZEJULA, made by the pharmaceutical company GSK, is a prescription medicine used for the maintenance treatment of adults with ovarian cancer, fallopian tube cancer or primary peritoneal cancer, when the cancer comes back. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy. It can also be used for treatment of adults with advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have been treated with three or more prior types of chemotherapy and who have tumors with a certain BRCA gene mutation, or a positive laboratory test, and whose cancer was in response to treatment with platinum-based chemotherapy, and who have progressed more than six months after the last treatment. For treatment in the late-line setting, your healthcare provider will perform a test to make sure that ZEJULA is right for you.

ZEJULA has serious risks such as bone marrow problems called MDS or a type of blood cancer called AML. Low blood cell counts are common. Tell your doctor about any weakness, tiredness, infections, fever, shortness of breath, blood in urine or stool, bruising, bleeding or weight loss. High blood pressure is common and can become serious. Nausea and constipation are also common.

Benefiting From More Recent Treatment Options

The idea of maintenance therapy to treat ovarian cancer is not new, Godoy said. Until recently, however, only intravenous forms of maintenance therapy were available, which required women to receive the treatment in clinics.

More recent treatment options for ovarian cancer include oral medications, like ZEJULA, which give women the ability to take it at home. ZEJULA is taken once a day.

Women living with ovarian cancer are often surprised to learn that maintenance therapies exist, she added. For the newly diagnosed, Godoy offered important advice.

If you have ovarian cancer, ask your OB/GYN to make a referral to a gynecologic oncologist and have a meeting with them to discuss your care, she said. Learn more about current treatments, including maintenance therapy, and be your own best advocate.

Jodi Helmer writes about health, science and innovation.

Important Safety Information

ZEJULA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of blood cancer called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with ZEJULA. MDS or AML may lead to death.

Symptoms of low blood cell counts (low red blood cells, low white blood cells, and low platelets) are common during treatment with ZEJULA. They can be a sign of serious bone marrow problems, including MDS or AML. These symptoms may include the following:

Your doctor will do blood tests to check your blood cell counts before treatment with ZEJULA. You will be tested weekly for the first month of treatment with ZEJULA, monthly for the next 11 months of treatment, and from time to time afterward.

High blood pressure is common during treatment with ZEJULA, and it can become serious. Your doctor will check your blood pressure and heart rate at least weekly for the first two months, then monthly for the first year, and as needed thereafter during your treatment with ZEJULA.

Before starting to take ZEJULA, tell your doctor about all of your medical conditions, including if you:

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of ZEJULA include the following:

o Heart not beating regularly

o Nausea

o Constipation

o Vomiting

o Pain in the stomach area

o Mouth sores

o Diarrhea

o Indigestion or heartburn

o Dry mouth

o Tiredness

o Loss of appetite

o Urinary tract infection

o Shortness of breath

o Cough

o Rash

o Changes in liver function or other blood tests

o Pain in your joints, muscles, and back

o Headache

o Dizziness

o Change in the way food tastes

o Trouble sleeping

o Anxiety

o Sore throat

o Changes in the amount or color of your urine

If you have certain side effects, then your doctor may change your dose of ZEJULA, temporarily stop, or permanently stop treatment with ZEJULA.

These are not all the possible side effects of ZEJULA. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For full prescribing information visit http://www.ZEJULA.com/prescribing-information.

NP-NIR-US-0004

NRPJRNA200001

Read the original:
When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journey - Forbes

Recommendation and review posted by Bethany Smith

A new proof-of-concept study has found a combination of two drugs, already approved by the FDA for other uses, may boost the release of stem cells from bone marrow and accelerate the healing of broken bones. Only demonstrated in animals at this stage, the researchers suggest clinical trials could progress rapidly considering the drugs have already been demonstrated as safe in humans.

"The body repairs itself all the time, says corresponding author on the study Sara Rankin. We know that when bones break they will heal, and this requires the activation of stem cells in the bone. However, when the damage is severe, there are limits to what the body can do of its own accord.

A great deal of current research is focusing on mesenchymal stem cell (MSC) therapies. MSCs are a type of adult stem cell that can grow into a variety of different cell types including muscle, fat or bone. Many current MSC treatments in development involve extracting a small number from a patient, growing them in laboratory conditions, then injecting them back into the patient.

The new research set out to investigate whether any currently approved drugs can function to mobilize the bodys natural ability in releasing MSCs, with a view on speeding up healing of bone fractures. A study published in the journal npj Regenerative Medicine, describes the testing of two already approved drugs in a rodent spinal injury model.

The two drugs tested were an immunostimulant called Plerixafor, used to stimulate the release of stem cells from bone marrow in cancer patients, and a beta-3 adrenergic agonist developed to help bladder control.

The results suggest the duo of drugs mobilize MSCs into the bloodstream and speed up the process of bone formation and healing by enhancing the binding of calcium to the injury site. Tariq Fellous, first author on the new study, suggests the next step is to investigate whether this drug combination enhances blood MSC levels in human subjects.

We first need to see if these medications release the stem cells in healthy volunteers, before we can then test them in patients with fractures, says Fellous. We have the drugs and know they are safe to use in humans - we just need the funding for the human trials.

The researchers say prior studies have identified circulating MSCs increase in volume following injuries such as burns, bone fractures, and even heart attack. The hypothesis is that the release of MSCs is a physiological process aiding general regeneration following injury, and if circulating numbers of MSCs could be pharmacologically enhanced then a variety of types of tissue regeneration could be accelerated.

It is important to note the current study only examined increases in circulating MSCs and the rate of spine injury healing compared to no drug treatment. The current research offers no indication whether the drug duo influences nerve healing or restores movement.

So, more work is certainly necessary to understand how clinically useful these results actually are. However, as the studys co-first author Andia Redpath notes, this re-purposing of existing medicines to boost stem cell activity is an easier, cheaper, and more efficient way to enhance healing compared to other, more complex and time-consuming, stem cell treatments in development.

Rather than devising new stem cell treatments from scratch that involve lengthy and expensive trials, our approach harnesses the power of the bodys own stem cells, using existing drugs, says Redpath. We already know the treatments in our study are safe, its now just a matter of exploring further if they help our bodies heal.

The new study was published in the journal npj Regenerative Medicine.

Source: Imperial College London

More:
Experimental study speeds up bone healing with 2 common medications - New Atlas

Recommendation and review posted by Bethany Smith

LEXINGTON, Ky. (WKYT) - Firefighters in Lexington spent their Saturday morning supporting their own with a pancake breakfast raising money for a young woman with a rare disease.

Chris OBryan has worked as a firefighter in Kentucky for 23 years. This past summer his daughter began experiencing stomach pain. After months of testing, doctors diagnosed her PCH, a rare disease caused by a mutation in bone marrow stem cells.

Once other Lexington Firefighters heard about OBryans daughter, they decided to help however they can.

Its seven days that this came together, said firefighter William Tabor.

Tabor initiated the breakfast without ever meeting OBryan and his family before.

Both men say that goes to show the family community within the fire department. Within just more than an hour of beginning the breakfast at 8 Saturday, they raised $5,000.

The money thats raised here is twofold, started OBryan. Some of its for my daughter and some of its for a Louisville firefighter who was tragically killed in Saint Louis.

Go here to read the rest:
Firefighter raise thousands within hours for one of their own - WKYT

Recommendation and review posted by Bethany Smith

FLORENCE, Ala. (AP) Cole Kelley grinned widely and waved Saturday (Feb. 15) as his head kept swiveling from one direction to the other to take in the amazing view surrounding him.

Hundreds of family members, friends, Mars Hill School classmates and other members of the community lined both sides of the school's parking lot to welcome the 8-year-old home.

The Mars Hill student and his parents, John and Caroline Kelley, had been away from home for 15 months while he has battled a rare disease.

That included a 460-day stay at the National Institutes of Health facility in Bethesda, Maryland, which is one of the few facilities with experience treating the disease dada2, which is a deficiency of the adenosine deaminase 2 (ADA2) enzyme.

According to dada2.org, the disease causes "recurrent strokes, severe systemic inflammation, immune deficiency, and damage to many of the body's tissues and organs."

The community organized the homecoming parade, which included an escort from Florence's police and fire departments, as well as people dressed in superhero outfits.

Along with Cole's classmates, Mars Hill High School cheerleaders joined the crowd, as did the school's football players, who showed up in their jerseys. The long reception line spanned the length of the parking lot coming off Cox Creek Parkway.

The procession made two laps through the parking lot amid loud cheers and flowing tears from the congregation before the family, clearly emotional from the outpouring, drove home.

"It's been amazing," Cole's cousin, Sara Beth Searcy, said while wearing a "Best Day Ever" shirt she bought during a Disney World trip Cole and the family took before his long hospital stay.

"This whole community has supported us from the very beginning," she said. "We could not have gotten through this without this entire community wrapping their arms around us."

Cole classmate Rogan Willingham held a sign that read "God answered our prayers."

"He's prayed, I don't know how many times a day, for Cole," his mother, Ginger Willingham, said.

"I'm glad he's back," Rogan said, adding he looks forward to being able to "play with him and all kinds of stuff."

"I was praying for him a lot," he said.

There were numerous other signs with messages, such as "Sweet Home, Alabama," "Super Cole" and "Welcome home, Buddy."

Emily Stutts, a friend of the family who helped organized the welcome, and fellow member of Jackson Heights Church of Christ, said Cole has been sick since he was 2 months old.

He had a bone transplant at the National Institutes.

"He lived off of having blood transfusions because his body did not make red blood cells," Stutts said. "After a while that became risky because his body can't filter out all the iron. So a bone marrow transplant was the only answer."

He was enrolled in the "Be the Match" bone marrow registry and was a match with a young man from Australia, who had volunteered to join the registry.

"He was able to give the bone marrow and they flew it over to Maryland and did the transplant," Stutts said. "It didn't take initially, and Cole has had three stem-cell transplants, all from the one donation from the Australian man.

"The fact that he's coming home is a miracle, because he had some very, very scary times that they didn't think he would survive. He had zero immune until Christmas day. That day his immune response occurred."

She said John and Caroline often talk about the amazing support they have been receiving back home. A community spaghetti supper, T-shirt sales and a Christmas fundraising event are among methods supporters have used to provide financial assistance for the parents, who have not been able to work during their son's hospitalization.

"The people at the hospital there can't believe the support that they've been given from this community," Stutts said. "They told them they see people from all over the world, but they've never seen the outpouring of love like they saw for the Kelleys.

"They deserve it. They're such good people."

Florence company High Cotton Homes provided assistance in a major way, Stutts said.

"They had to have all new heating and air units and vents put in and a water purification system, all new flooring and all new duct work because of his immune system," she said. "High Cotton took that on, got donations and completely remodeled his room and made it so Cole would have his own bathroom to help with germ prevention."

Cole still is susceptible to sickness and will continue to have medical appointments, Stutts said.

"His liver was damaged from the transplant so he's going to go to Vanderbilt for them to check his liver," she said. "There's still things that need to be addressed, but as far as his bone marrow, that is doing OK."

Stutts said Cole's disease has not kept him down.

"He is full of life," she said. "He's a happy kid. Even though he's been sick, if you had seen him, you would have never know it. He's made a huge impact on the people at the National Institutes for Health because no child's been there that long. That became his family. They had a going-away party at one of the doctor's homes."

The emotions of Saturday's homecoming were obvious among the crowd, many of whom hugged one another and cried.

"The one thing I kept hearing from everybody is it was more emotional than they through it would be," said Ronnie Pannell, family minister at Jackson Heights. It's been a big show of love. Mars Hill loves Cole Kelley, there's no doubt about that.

Originally posted here:
Community give child a hero's homecoming - Thehour.com

Recommendation and review posted by Bethany Smith

Alfie Commons and mum Lorna, 40, met Christin Bouvier, 34, for the first time on Wednesday after spending more than two years communicating via anonymous letters due to donation laws.

Alfie, from Toton, Notts, was diagnosed with acute lymphoblastic leukaemia (ALL) at seven months after he had a cold for six weeks.

After chemotherapy failed, Alfie was put on a trial immunotherapy drug which helped him to recover to be eligible for a stem cell transplant.

Unable to find a family match, his family found Christin on a worldwide register operated by blood cancer charity DKMS. She donated her cells in a one-hour op and they were flown to the UK and slowly passed into Alfies body in August 2016.

When the teacher, from Schwerin, Germany, was finally allowed to meet the family at Chiswick Town Hall in west London, the little boy gave a gift of Lacoste Pink perfume.

Mum-of-two Lorna, who works in HR, said: The meet-up was just amazing, it was everything we could have possibly dreamed of there were lots of hugs and tears.

It didnt feel like I was meeting her for the first time because wed been chatting for so long before.

As a family, we owe so much to Christin, words of thanks will never feel enough.

Christin just cried when she heard the recipient was a baby. She said: After I donated my bone marrow and the anaesthetic wore off, I called DKMS.

They told me that Alfie was a small baby and living in the UK but couldnt tell me any more due to the laws. When I found out Alfie was responding to treatment, so many tears of joy ran down my face. I still cant describe that moment.

Its a moment that is always with me. Whenever I feel a bit down, I think back to it as it always brings me so much happiness! She added that the meeting was so amazing. I was very nervous and shaking at first and when we finally met we cried a lot and hugged.

Alfie was shy at first but after a bit of time he became more comfortable and we played with some balloons and had a slice of cake.

After the transplant, Alfie developed a deadly immune condition, but this was controlled by medication. He was given the cancer all-clear in 2017 and has started school.

Lorna added: I just want more people to sign up to become donors theres a match for everyone.

Read more here:
From Germany with love: Alfie, four, meets his stem cell saviour - Express

Recommendation and review posted by Bethany Smith

DEFINITIONLeukemia is a Cancer of blood forming tissues including bone marrow and the lymphatic system.This type of cancer hinders the body's ability to fight infection, leukemia involves the white blood cells.

CAUSES OF LEUKEMIALeukemia can develop due to a problem with blood cell production.

Several factors have been identified which increase the risk of having the cancer:

A family history of leukemiaSmokingGenetic disorder such as Down syndromeExposure to chemicals such as benzeneExposure to high levels of radiationTYPES OF LEUKEMIALeukemia can be Acute or Chronic. In Acute leukemia, Cancer cell multiply quickly while in Chronic leukemia, the disease progresses slowly and early symptoms may be very mild.

Leukemia can also be classified according to types of cells which are myelogenous leukemia and lymphotic leukemia involving myeloid cells and lymphocytes respectively.

SYMPTOMS OF LEUKEMIAExcessive sweating most especially in the nightFatigue and weaknessUnintentional weight lossFever or chillsFrequent infectionsBleeding easily and bruising easilyEnlargement of the liver or spleenLEUKEMIA IN PREGNANCYLeukemia affects approximately 1 in 10000 pregnancies.Women with leukemia have non-specific symptoms and some of them could also be attributed to pregnancy.

The damage in the fetus is correlated with the time of exposition and the fetus is most vulnerable during organnogenesis phase, Although chemotherapy has effect in the fetus, there are reports of cases with successful pregnancy.

It is necessary to study the relation among chemotherapy, the leukemia and the fetus in long term studies where fetus has been exposed to chemotherapy agents and is reported with normal characteristics at birth.

ENZYMES DEFICIENT IN LEUKEMIABlast cells from 100 cases of Acute leukemia were evaluated for the presence of methylthioadenosine phosphorylase (MTAase), an enzyme important in polyamine metabolism.

Ten cases (10%) had undetectable levels of MTAase activity. A relatively high frequency (38%) of MTAase deficiency was seen in all of T-cell origin.

MTAase deficiency occurs in a wide variety of acute leukemia, that the lack of enzyme activity is specific in malignant cells. The absence of MTAase in some leukemia may be therapeutically exploitable.

TREATMENT OF LEUKEMIALeukemia is usually treated by a hematologist-oncologist. These are doctors who specialize in blood disorders and cancer.

The treatment depends on the type and stage of the cancer, the treatment includes the following:

Chemotherapy uses drugs to kill leukemia cells.Radiation therapy uses high energy radiation to damage leukemia cells and inhibit their growth.

Stem cell transplantation replaces diseased bone marrow with healthy bone marrow.

Biological or immune therapy uses treatments that help your immune system recognize and attack cancer cells.

Targeted therapy uses medication advantages of vulnerabilities in cancer cells.

Excerpt from:
Leukemia: Cancer Of The Blood - Modern Ghana

Recommendation and review posted by Bethany Smith

Medical ResearchThe belief that acute stress can turn hair gray is a popular one, but until now it hasnt been scientifically proven.

But findings that appeared in the publication Nature indicate that the belief may be more than a myth. The study, which used mice as models, was funded in part by the National Institutes of Healths National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other NIH components.

Hair color is determined by cells called melanocytes, which produce the pigment melanin. New melanocytes are made from melanocyte stem cells that live within the hair follicle at the base of the hair strand. As we age, these stem cells gradually disappear. The hair that regrows from hair follicles that have lost melanocyte stem cells has less pigment and appears gray.

A research team, led by Dr. Ya-Chieh Hsu of Harvard University, used mice to examine stress and hair graying. The mice were exposed to three types of stress involving mild, short-term pain, psychological stress, and restricted movement. All caused noticeable loss of melanocyte stem cells and hair graying.

Having established a link between stress and graying, the scientists then explored several potential causes, including the role of the stress hormone corticosterone, but altering its levels didnt affect stress-related graying.

The researchers eventually turned to the neurotransmitter noradrenaline, which, along with corticosterone, was elevated in the stressed mice. They found that noradrenaline, also known as norepinephrine, was key to stress-induced hair graying. By injecting noradrenaline under the skin of unstressed mice, the researchers were able to cause melanocyte stem cell loss and hair graying.

Noradrenaline is produced mostly by the adrenal glands. However, mice without adrenal glands still showed stress-related graying. Noradrenaline is also the main neurotransmitter of the sympathetic nervous system, which is responsible for the fight-or-flight reaction in response to stress.

Ultimately, the team discovered that signaling from the sympathetic nervous system plays a critical role in stress-induced graying. Sympathetic nerves extend into each hair follicle and release noradrenaline in response to stress. Normally, the melanocyte stem cells in the follicle are dormant until a new hair is grown. Noradrenaline causes the stem cells to activate.

Using fluorescent labelling, the researchers observed the stem cells change to melanocytes and migrate away from their reserve in the hair follicle. With no remaining stem cells, no new pigment cells can be made, and any new hair becomes gray, then white.

When we started to study this, I expected that stress was bad for the body but the detrimental impact of stress that we discovered was beyond what I imagined, Hsu says. After just a few days, all of the melanocyte stem cells were lost. Once theyre gone, you cant regenerate pigments anymore. The damage is permanent.

The authors highlight the need to further study the interactions between the nervous system and stem cells in different tissues and organs. A news release from the NIH said that the knowledge gained in this work will be useful in future investigations into the impact of stress on the body and the development of new interventions.

See more here:
Stress and Gray Hair - ThirdAge

Recommendation and review posted by Bethany Smith

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD

Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020

NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc. (KDMN) today announced expanded results from the previously reported interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD). The data were presented today in the oral latebreaker session at the 2020 Transplantation & Cellular Therapy (TCT) Meetings.

As announced in November 2019, KD025 met the primary endpoint of Overall Response Rate (ORR) at the study's planned interim analysis, two months after completion of enrollment. KD025 showed statistically significant and clinically meaningful ORRs of 64% with KD025 200 mg once daily (95% Confidence Interval (CI): 51%, 75%; p<0.0001) and 67% with KD025 200 mg twice daily (95% CI: 54%, 78%; p<0.0001). In the expanded KD025-213 dataset presented today, ORRs were consistent with the previously reported interim analysis across key subgroups, including in patients with four or more organs affected by cGVHD (n=69; 64%), patients who had prior treatment with ibrutinib (n=45; 62%) and patients who had prior treatment with ruxolitinib (n=37; 62%). Three patients achieved a Complete Response. Responses were observed in all affected organ systems, including in organs with fibrotic disease. KD025 has been well tolerated: adverse events were consistent overall with those expected to be observed in cGVHD patients receiving corticosteroids, and no apparent increased risk of infection was observed. Additional secondary endpoints, including duration of response, corticosteroid dose reductions, Failure-Free Survival, Overall Survival and Lee Symptom Scale reductions continue to mature and will be available later in 2020.

"KD025 has been well tolerated and has already demonstrated high response rates in patients with severe and complex cGVHD after a median of five months of follow-up," said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School; Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute and a KD025-213 study investigator and Steering Committee member.

"We are extremely pleased with the interim outcomes of this pivotal trial of KD025 in cGVHD, which track closely our findings from our earlier Phase 2 study. KD025 achieved robust response rates across all subgroups of this difficult-to-treat patient population, who had a median of four prior lines of therapy, and 73% of whom had no response to their last line of treatment," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We plan to meet with the FDA for a pre-NDA meeting in March 2020 and to announce topline results from the primary analysis of this trial in Q2 2020."

At the TCT Meetings, Kadmon also presented long-term follow-up data from KD025-208, its ongoing Phase 2 study of KD025 in cGVHD (Abstract #15205). These data were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in December 2019.

About the ROCKstar (KD025-213) Trial

KD025-213 is an ongoing open-label trial of KD025 in adults and adolescents with cGVHD who have received at least two prior lines of systemic therapy. Patients were randomized to receive KD025 200 mg once daily or KD025 200 mg twice daily, enrolling 66 patients per arm. Statistical significance is achieved if the lower bound of the 95% CI of ORR exceeds 30%.

While the ORR endpoint was met at the interim analysis, which was conducted as scheduled two months after completion of enrollment, topline data from the primary analysis of the KD025-213 study, six months after completion of enrollment, will be reported in Q2 2020. Full data from the primary analysis will be submitted for presentation at an upcoming scientific meeting.

About KD025

KD025 is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates immune response as well as fibrotic pathways. In addition to cGVHD, KD025 is being studied in an ongoing Phase 2 clinical trial in adults with diffuse cutaneous systemic sclerosis (KD025-209). KD025 was granted Breakthrough Therapy Designation and Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with cGVHD who have received at least two prior lines of systemic therapy.

Story continues

About cGVHD

cGVHD is a common and often fatal complication following hematopoietic stem cell transplantation. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are currently living with cGVHD, and approximately 5,000 new patients are diagnosed with cGVHD per year.

About Kadmon

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe, China, Japan and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel (xx) the potential benefits from any of our product candidates being granted orphan drug or breakthrough designation; (xxi) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; and/or (xxii) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact Information

Ellen Cavaleri, Investor Relations646.490.2989ellen.cavaleri@kadmon.com

SOURCE: Kadmon Holdings, Inc.

View source version on accesswire.com: https://www.accesswire.com/577466/Kadmon-Announces-Expanded-Results-of-Interim-Analysis-of-Pivotal-Trial-of-KD025-in-cGVHD

Originally posted here:
Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD - Yahoo Finance

Recommendation and review posted by Bethany Smith

Stress may play a key role in just how quickly hair goes from colored to ashen.

Scientists have long understood some link is possible between stress and grey hair.

But this new research more deeply probes the exact mechanisms at play.

The researchers initial tests looked closely at cortisol, the stress hormone that surges in the body when a person experiences a fight or flight response.

Its an important bodily function, but the long-term presence of heightened cortisol links to a host of negative health outcomes.

But the culprit ended up being a different part of the bodys fight or flight response the sympathetic nervous system.

These nerves are all over the body, including making inroads to each hair follicle, the researchers reported.

Chemicals released during the stress response causes pigment producing stem cells to activate prematurely, depleting the hairs reserves of color.

The detrimental impact of stress that we discovered was beyond what I imagined, a lead study author said.

After just a few days, all of the pigment-regenerating stem cells were lost.

Once theyre gone, you cant regenerate pigments anymore. The damage is permanent.

But stress isnt the only reason that most people get grey hair.

In most cases, its simple genetics.

Gray hair caused by loss of melanocytes (pigment cells) in the hair follicle.

This happens as we age and, unfortunately, there is no treatment that can restore these cells and the pigment they produce, melanin, a dermatologist told.

Genetic factors determine when you go grey.

There is nothing that can be done medically to prevent this from happening when it is genetically predetermined to happen.

That doesnt mean environmental factors such as stress dont play a role.

Smoking, for instance, is a known risk factor for premature graying.

So kick the habit if you want to keep that color a little longer.

Other contributing factors to premature graying include deficiencies in protein, vitamin B-12, copper, and iron as well as aging due in part to an accumulation of oxidative stress.

That stress prompted by an imbalance between free radicals and antioxidants in your body that can damage tissue, proteins, and DNA.

And some degree of oxidative stress is a natural part of life.

Changes you can pursue to delay premature grays include eating a diet high in omega-3 fatty acids such as walnuts and fatty fish.

It doesnt spend too much time in the skin-damaging and hair-damaging ultraviolet light of the sun, and taking vitamin B-12 and vitamin B-6 supplements.

That said, if you are going gray prematurely, it wouldnt hurt to go have a checkup just in case natural genetic factors arent the sole culprit.

Read the original post:
Stress could be a major cause of grey hair - BOL News

Recommendation and review posted by Bethany Smith